Drugs / RBD7022
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07074236 | Jul 2025 → Jan 2026 overdue | hyperlipidemia | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05912296 | May 2023 → Mar 2025 | hyperlipidemia | Suzhou Ribo Life Science Co. Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-09-01 | Ribocure Pharmaceuticals AB | Results Ribo showcases new clinical data from its leading siRNA programs at ESC 2025, underscoring significant progress and achievements in advancing cardiovascular therapies ribocure.com ↗
Using PCSK9 levels as a marker of target engagement, in patients with and without statin background therapy, the administration of RBD7022 demonstrated a maximal reduction of up to 75%, maintaining this level of suppression at 6 months follow-up. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-09-01 | Ribocure Pharmaceuticals AB | Ribo showcases new clinical data from its leading siRNA programs at ESC 2025, underscoring significant progress and achievements in advancing cardiovascular therapies ribocure.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RBD7022 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05912296 ↗ |
| Route | Subcutaneous | “Subcutaneously Administered RBD7022 in Healthy Subjects.” NCT05912296 ↗ |